厄洛替尼治疗EGFR突变型NSCLC脑转移临床观察被引量：1

下载PDF

导出

摘要目的:观察厄洛替尼联合全脑放疗治疗EGFR突变型非小细胞肺癌(NSCLC)脑转移的临床疗效及预后情况分析。方法:2015年10月-2016年7月收治EGFR突变型NSCLC脑转移患者60例,分为对照组和观察组,各30例。所有患者均采用全脑放疗,观察组在此基础上加用厄洛替尼治疗,观察两组的临床疗效和预后情况。结果:对照组ORR和DCR分别为13.33%和63.33%,观察组ORR和DCR分别为56.67%和90.00%,观察组的ORR和DCR高于对照组,对比差异有统计学意义(P<0.05)。对照组中位无进展生存时间8个月,观察组无进展生存时间6个月,对照组无进展生存率60.00%(18/30),观察组无进展生存率83.33%(25/30),观察组的无进展生存率高于对照组(P<0.05)。结论:厄洛替尼治疗EGFR突变型NSCLC脑转移的临床疗效较高,预后情况较好,值得在临床中推广实施。

作者刘亚玲

机构地区云南省曲靖市第一人民医院肿瘤科

出处《中国社区医师》 2019年第10期53-54,共2页 Chinese Community Doctors

关键词非小细胞肺癌 EGFR突变型厄洛替尼预后

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献4

1袁岳宏,林连兴.EGFR-TKI联合同步放疗一线治疗EGFR突变型Ⅳ期非小细胞肺癌的临床观察[J].广东医学,2012,33(12):1767-1769. 被引量：14
2李沫,纪秀杰,周迪.厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移的临床疗效[J].中国老年学杂志,2015,35(18):5184-5186. 被引量：23
3孙文宇,马克威.EGFR-TKI治疗非小细胞肺癌脑转移的研究进展[J].中国老年学杂志,2016,36(20):5213-5215. 被引量：8
4王小磊,刘德泽,王民,栾天燕.厄洛替尼联合全脑放疗治疗非小细胞肺癌脑转移的临床观察[J].国际肿瘤学杂志,2015,42(11):809-812. 被引量：19

二级参考文献28

1WILLIAMS K J, TELFER B A, STRATFORD I J, et al. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor- tyro- sine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model[J]. Br J Cancer, 2002, 86(7) : 1157 - 1161.
2CHINNAIYAN P, HUANG S, VALLABHANENI G, et al. Mech- anisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib ( Tarceva ) [ J ]. Cancer Res, 2005, 65 ( 8 ) : 3328 - 3335.
3PARRA H S, CAVINA R, LATI'ERI F, et al. Analysis of epider- mal growth factor receptor expression as a predictive factor for re- sponse to gefitinib( " Iressa", ZD1839 ) in non - small - cell lung cancer[J]. BrJCancer, 2004, 91(2): 208-212.
4MOK T, WU Y L, THONGPRASERT S, et al. Gefitinib or carbo- platin- paclitaxel in pulmonary adenocarcinoma [ J ]. N Engl J Med, 2009, 361(10): 1 -11.
5KOBAYASHI K, INOUE A, MAEMONDO M, et al. First- line gefitinib versus first - line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non - small cell lung cancer ( NSCLC ) patients (pts) with EGFR mutations: a phase llI study (002) by North East Japan Gefitinib Study Group[J]. J Clin Oncol, 2009, 27(Snvvl): 8016.
6WU J Y, WU S G, YANG C H, et al. Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations [J]. Lung Cancer, 2011, 72(2) : 205 -212.
7张秀萍,李健,黄赖机,张占书.厄洛替尼联合全脑放射治疗非小细胞肺癌多发脑转移的初步观察[J].中国神经肿瘤杂志,2007,5(3):180-182. 被引量：12
8Shigematsu H,Lin L,Takahashi T,et al.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[].Journal of the National Cancer Institute.2005
9Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality pre- dictians for the year 2013 [ J ]. Ann Oncol, 2013, 24 ( 3 ) : 792 -800.
10Olmez I, Donahue BR, Butler JS, et al. Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT)and Erlotinib treatment in patients with non- small cell lung cancer ( NSCLC ) with brain metastasis [ J ]. Lung Can- cer, 2010, 70(2) : 174-179.